Combination versus sequential single agent chemotherapy for metastatic breast cancer (Q24201726)

2

0 references

author name string

Rachel F Dear

1

0 references

Marisa C Jenkins

3

0 references

Alexandra Barratt

4

0 references

Martin HN Tattersall

Cochrane Database of Systematic Reviews

5

0 references

publication date

18 December 2013

0 references

published in

0 references

cites work

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Coo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Addition of drug/s to a chemotherapy regimen for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Is breast cancer survival improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008792.PUB2

10.1002/14651858.CD008792.PUB2

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

24347031

1 reference

Consolidated OpenCitations Corpus – April 2017